The ratings of three Life Science stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
BG Medicin’s (NASDAQ:BGMD) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that it identifies. In Portfolio Grader’s specific subcategories of Equity, Cash Flow, and Sales Growth, BGMD also gets an F. For more information, get Portfolio Grader’s complete analysis of BGMD stock.
This is a rough week for Techne Corp. (NASDAQ:TECH). The company’s rating falls to D from the previous week’s C. Techne develops, manufactures, and sells biotechnology products and hematology calibrators and controls. To get an in-depth look at TECH, get Portfolio Grader’s complete analysis of TECH stock.
Luminex’s (NASDAQ:LMNX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Luminex develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The stock also gets an F in Earnings Surprise. The stock currently has a trailing PE Ratio of 61.40. For more information, get Portfolio Grader’s complete analysis of LMNX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.